BioSpace News Archive

Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY) today commented on the favorable decision by the U.S. Patent and Trademark Office (USPTO) to deny a Petition for Reexamination concerning a patent covering the active ingredient in WAKIX® (pitolisant).

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from the APHENITY clinical trial and long-term extension study will be presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2023 which is being held from Aug. 29 to Sept. 1 in Jerusalem, Israel.

Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, announced that global biopharmaceutical company and cell therapy developer Bristol Myers Squibb (NYSE: BMY) has joined its Technology Adoption Partnership (TAP) program.

Tris Pharma, Inc. announced that the company has been awarded a grant expected to provide up to $16.6M over five years from the National Institute on Drug Abuse, part of the National Institutes of Health.

NanoString Technologies, Inc., a provider of life science tools for discovery and translational research, announced that Todd Garland has been appointed Chief Commercial Officer, effective August 28, 2023.

Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, has been named to Fierce Biotech’s 2023 “Fierce 15” list, designating it as one of the most outstanding early-stage biotechnology companies in the industry.

KalVista Pharmaceuticals, Inc. announced the acceptance of multiple abstracts at the 2023 HAEi Regional Conference EMEA meeting taking place in Munich, Germany from September 1-3.

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) today announced that it will be presenting analyses highlighting patient-focused endpoints from its Essential1 study of ulixacaltamide (PRAX-944) in essential tremor (ET) at The International Parkinson and Movement Disorder Society’s (MDS) International Congress of Parkinson’s Disease and Movement Disorders®, taking place in Copenhagen, Denmark.

Genelux Corporation, a late clinical-stage immuno-oncology company, announced that Lourie S. Zak will join the company as Chief Financial Officer, effective August 28, 2023.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that all samples and data required for a readout of topline results from the Phase 2b SYMMETRY study have been collected, which supports the expected timing of readout in October of this year.